Skip to main content

Advertisement

SpringerLink
Log in

Caution should be taken in the methodology used to confirm c.156_157insAlu BRCA2 mutation

  • Letter to the Editor
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Peixoto A, Santos C, Rocha P et al (2008) The c.156_157insAlu BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA mutations in northern/central Portugal. Breast Cancer Res Treat (Mar):25 (Epub ahead of print)

  2. Machado PM, Brandao RD, Cavaco BM et al (2007) Screening for a BRCA2 rearrangement in high-risk rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes. J Clin Oncol 25:2027–2034. doi:10.1200/JCO.2006.06.9443

    Article  PubMed  CAS  Google Scholar 

  3. Teugels E, De Brakeleer S, Goelen G et al (2005) De novo Alu element insertions targeted to a sequence common to the BRCA1 and BRCA2 genes. Hum Mutat 26:284. doi:10.1002/humu.9366

    Article  PubMed  Google Scholar 

  4. Díez O, Gutiérrez-Enríquez S, Ramón y Cajal T et al (2007) Caution should be used when interpreting alterations affecting the exon 3 of the BRCA2 gene in breast/ovarian cancer families. J Clin Oncol 25:5035–5036. doi:10.1200/JCO.2007.13.4346

    Article  PubMed  Google Scholar 

  5. Santarosa M, Viel A, Boiocchi M (1999) Splice variant lacking the transactivation domain of the BRCA2 gene and mutations in the splice acceptor site of intron 2. Genes Chromosomes Cancer 26:381–382. doi:10.1002/(SICI)1098-2264(199912)26:4<381::AID-GCC14>3.0.CO;2-N

    Article  PubMed  CAS  Google Scholar 

  6. Zou J, Hirose Y, Siddique H et al (1999) Structure and expression of variant BRCA2a lacking the transactivation domain. Oncol Rep 6:437–440

    PubMed  CAS  Google Scholar 

  7. Speevak MD, Young SS, Feilotter H et al (2003) Alternatively spliced, truncated human BRCA2 isoforms contain a novel coding exon. Eur J Hum Genet 11:951–954. doi:10.1038/sj.ejhg.5201063

    Article  PubMed  CAS  Google Scholar 

  8. Koul A, Nilbert M, Borg A (1999) A somatic mutation in RER endomentrial carcinomas that specifically deletes the amino-terminal transactivation domain. Genes Chromosomes Cancer 24:207–212. doi:10.1002/(SICI)1098-2264(199903)24:3&lt;207::AID-GCC5&gt;3.0.CO;2-3

    Article  PubMed  CAS  Google Scholar 

  9. Machado PM, Cavaco BM, Brandao RD et al (2007) In reply to: Díez O, Gutiérrez-Enríquez S, Ramón y Cajal T et al. Caution should be used when interpreting alterations affecting the exon 3 of the BRCA2 gene in breast/ovarian cancer families. J Clin Oncol 25:5036–5038. doi:10.1200/JCO.2007.13.5442

    Article  Google Scholar 

  10. Nordling M, Karlsson P, Wahlstrom J et al (1998) A large deletion disrupts the exon 3 transcription activation domain of the BRCA2 gene in a breast/ovarian cancer family. Cancer Res 58:1372–1375

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Molecular Biology Department, Instituto Português de Oncologia de Lisboa, Francisco Gentil, Lisbon, Portugal

    Patricia Machado & Fatima Vaz

  2. Breast Cancer Risk Evaluation Clinic, Instituto Português de Oncologia de Lisboa, Francisco Gentil, Lisbon, Portugal

    Fatima Vaz

Authors
  1. Patricia Machado
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fatima Vaz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fatima Vaz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Machado, P., Vaz, F. Caution should be taken in the methodology used to confirm c.156_157insAlu BRCA2 mutation. Breast Cancer Res Treat 116, 617–618 (2009). https://doi.org/10.1007/s10549-008-0124-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-008-0124-0

Keywords

Search

Navigation